Mavyret, a medication used to treat chronic hepatitis C virus (HCV) infection, is a combination drug containing glecaprevir and pibrentasvir [1]. It is designed to target all genotypes of HCV [2].
How does Mavyret work to treat Hepatitis C?
Mavyret functions as a two-part treatment by inhibiting key viral proteins essential for HCV replication. Glecaprevir is an NS3/4A protease inhibitor, while pibrentasvir is an NS5A inhibitor [1]. By blocking these targets, Mavyret effectively prevents the virus from multiplying and spreading within the body [3].
What types of Hepatitis C does Mavyret treat?
Mavyret is indicated for the treatment of chronic HCV infection in adults across all major genotypes, including genotypes 1 through 6 [2]. This broad-spectrum coverage makes it a versatile option for a wide range of patients.
How long does a Mavyret treatment course typically last?
The duration of Mavyret treatment depends on the specific HCV genotype and whether the patient has any signs of cirrhosis. For most patients without cirrhosis and with genotypes 1, 2, 3, 4, 5, or 6, treatment is typically 8 weeks. For patients with cirrhosis or those treated previously for genotype 1 infection who did not respond to prior treatment, the course is usually 12 weeks [4].
Are there any alternatives to Mavyret for Hepatitis C treatment?
Yes, several other direct-acting antiviral (DAA) regimens are available for treating chronic hepatitis C. These often include different combinations of drugs targeting various parts of the HCV life cycle. Examples include Harvoni, Epclusa, Vosevi, and Zepatier, among others [5]. The choice of treatment depends on factors such as HCV genotype, prior treatment history, and the presence of liver disease [6].
What is the patent status for Mavyret?
Mavyret is protected by various patents. DrugPatentWatch.com tracks patent information for drugs like Mavyret, providing details on patent expiry dates and any associated litigation [7]. Patent expiry dates are crucial as they determine when generic versions of the drug can enter the market.
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie Inc. [1].